The Neuroendocrine Tumor Research Foundation (NETRF) recently announced changes to the Board of Scientific Advisors (BOSA), extending its sincerest appreciation for the participation of Dung Thi Le, MD, and welcoming Jennifer Eads, MD, as the BOSA’s newest member.
Dr. Le, who is associate professor of Oncology at Johns Hopkins University School of Medicine and a physician at the Johns Hopkins Kimmel Cancer Center, is leaving the BOSA after serving for seven years.
“It was an honor to serve on the Board of Scientific Advisors as an immunotherapy specialist and to witness the knowledge created as a result of the discoveries made by investigators supported by NETRF,” said Dr. Le.
NETRF welcomes Dr. Eads as a new member of BOSA. Dr. Eads is an associate professor of Medicine, the physician lead for GI Clinical Research, and the director of the Neuroendocrine Tumor Program at the Perelman Center for Advanced Medicine at the University of Pennsylvania. Among her clinical interests, Dr. Eads explores DNA repair and novel therapeutics related to neuroendocrine tumors.
The BOSA is a volunteer board of highly distinguished clinical and research leaders who share NETRF’s commitment to advancing the understanding, diagnosis, and treatment of neuroendocrine cancer. The BOSA is central to the rigorous scientific review that allows NETRF to quickly identify the most promising grant applications and fund projects that have the most potential to transform the NET landscape.
All members of the Board of Scientific Advisors are recognized experts in medical research, published authors in the top peer-reviewed medical journals, and leaders of collaborative research projects at top-ranked universities and institutes.